Neurodevelopmental Outcomes at Age 5 Years After Prophylactic Early High-Dose Recombinant Human Erythropoietin for Neuroprotection in Very Preterm Infants

Prespecified secondary neurodevelopmental outcomes of the trial cohort at early school age were assessed (n=448) and no statistically significant differences were found at 5 years in children born very preterm treated with prophylactic early high-dose rhEpo vs saline.

Journal of the American Medical Association